SG10201909796PA - Chemosensory receptor ligand-based therapies - Google Patents
Chemosensory receptor ligand-based therapiesInfo
- Publication number
- SG10201909796PA SG10201909796PA SG10201909796PA SG10201909796PA SG 10201909796P A SG10201909796P A SG 10201909796PA SG 10201909796P A SG10201909796P A SG 10201909796PA SG 10201909796P A SG10201909796P A SG 10201909796PA
- Authority
- SG
- Singapore
- Prior art keywords
- chemosensory receptor
- receptor ligand
- based therapies
- methods
- chemosensory
- Prior art date
Links
- 230000000723 chemosensory effect Effects 0.000 title abstract 4
- 239000003446 ligand Substances 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000031964 Other metabolic disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
Abstract
Chemosensory Receptor Ligand-Based Therapies Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention. No fig.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/763,926 US9901551B2 (en) | 2009-04-20 | 2010-04-20 | Chemosensory receptor ligand-based therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201909796PA true SG10201909796PA (en) | 2019-11-28 |
Family
ID=44834962
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201909796P SG10201909796PA (en) | 2010-04-20 | 2010-10-19 | Chemosensory receptor ligand-based therapies |
SG10201503098PA SG10201503098PA (en) | 2010-04-20 | 2010-10-19 | Chemosensory receptor ligand-based therapies |
SG2012077558A SG184935A1 (en) | 2010-04-20 | 2010-10-19 | Chemosensory receptor ligand-based therapies |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201503098PA SG10201503098PA (en) | 2010-04-20 | 2010-10-19 | Chemosensory receptor ligand-based therapies |
SG2012077558A SG184935A1 (en) | 2010-04-20 | 2010-10-19 | Chemosensory receptor ligand-based therapies |
Country Status (14)
Country | Link |
---|---|
US (1) | US9901551B2 (en) |
EP (1) | EP2560660A4 (en) |
JP (1) | JP5907952B2 (en) |
KR (1) | KR101881608B1 (en) |
CN (2) | CN106039313A (en) |
AR (1) | AR078678A1 (en) |
BR (1) | BR112012026838A2 (en) |
CA (1) | CA2800470A1 (en) |
EA (1) | EA201270767A1 (en) |
IL (1) | IL222586A0 (en) |
MX (1) | MX2012012157A (en) |
SG (3) | SG10201909796PA (en) |
WO (1) | WO2011133180A1 (en) |
ZA (1) | ZA201208277B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9757346B2 (en) | 2008-09-03 | 2017-09-12 | Volant Holdings Gmbh | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
US20130281394A1 (en) * | 2010-10-19 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory Receptor Ligand-Based Therapies |
US9486463B2 (en) | 2010-10-19 | 2016-11-08 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
US20130303466A1 (en) * | 2010-10-19 | 2013-11-14 | Elcelyx Therapeutics, Inc. | Chemosensory Receptor Ligand-Based Therapies |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
MX2013007884A (en) * | 2011-01-07 | 2013-09-13 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies. |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US10195136B2 (en) * | 2011-08-24 | 2019-02-05 | Avon Products, Inc. | Collagen and elastin stimulating compositions and uses thereof |
EA033067B1 (en) | 2012-01-06 | 2019-08-30 | Элселикс Терапьютикс, Инк. | Method for treating metabolic disorders in a patient having a contraindication for a biguanide compound |
MX2014008190A (en) | 2012-01-06 | 2015-02-04 | Elcelyx Therapeutics Inc | Biguanide compositions and methods of treating metabolic disorders. |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
WO2016205754A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
AU2016299590B2 (en) * | 2015-07-27 | 2022-09-01 | Suntory Holdings Limited | Composition containing cyclic dipeptide and sweetening agent |
EP3568411B1 (en) * | 2017-01-13 | 2024-03-06 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
WO2019165309A1 (en) * | 2018-02-23 | 2019-08-29 | Ambra Bioscience Llc | Compositions and methods for hunger control and weight management |
US10737259B2 (en) * | 2018-08-31 | 2020-08-11 | Pall Corporation | Salt tolerant anion exchange medium |
BR112022022473A2 (en) * | 2020-05-06 | 2022-12-13 | Corcept Therapeutics Inc | CYCLOHEXYL PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATOR FORMULATIONS |
US11827608B2 (en) | 2020-12-21 | 2023-11-28 | Corcept Therapeutics Incorporated | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
CN115252630B (en) * | 2022-09-02 | 2024-02-09 | 深圳技术大学 | Application of phellodendron ketone in preparing medicine for preventing, improving or treating non-alcoholic fatty liver disease |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
JPS58403B2 (en) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L- Ascorbine Sanseizaino Seizouhou |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
JPS5825980B2 (en) | 1976-02-12 | 1983-05-31 | ヤマサ醤油株式会社 | Cyclic nucleotide quantification method |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
JPS62195323A (en) | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | Gastric resident particle |
US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
JP3249147B2 (en) * | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | Oral preparation containing bioactive protein |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
WO1992017585A1 (en) | 1991-04-05 | 1992-10-15 | The Trustees Of Columbia University In The City Of New York | Odorant receptors ans uses thereof |
DE69206993T2 (en) | 1991-07-19 | 1996-05-30 | Uniroyal Chem Co Inc | COMPOSITIONS FOR USING FILMS ON SEED |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
DE69322077T2 (en) | 1992-03-25 | 1999-04-08 | Depomed Inc | ORAL PHARMACEUTICAL FORMS BASED ON HYDROXYETHYL CELLULOSE WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES |
US5322697A (en) | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
FR2704146B1 (en) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules of acetylsalicylic acid with controlled release. |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5589194A (en) | 1993-09-20 | 1996-12-31 | Minnesota Mining And Manufacturing Company | Method of encapsulation and microcapsules produced thereby |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
IL108205A0 (en) | 1993-12-28 | 1994-04-12 | Yeda Res & Dev | Olfactory genes and receptors |
US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
IT1270216B (en) | 1994-06-14 | 1997-04-29 | Recordati Chem Pharm | METHOD OF STABILIZATION OF BIOLOGICALLY ACTIVE COMPOUNDS BY MICROGRANULES COVERED SUSPENDABLE IN FOOD FLUIDS |
ES2100142T3 (en) | 1994-07-08 | 2002-03-01 | Astrazeneca Ab | DOSAGE FORM IN TABLETS I CONSTITUTED BY MULTIPLE UNITS. |
FR2725623A1 (en) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION |
MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
AU1118197A (en) | 1995-11-09 | 1997-05-29 | Johns Hopkins University School Of Medicine, The | Novel sperm receptors |
CN1125574A (en) | 1995-11-10 | 1996-07-03 | 邵洪 | Enteric-soluble glutamine |
GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US5874243A (en) | 1997-03-28 | 1999-02-23 | Smithkline Beecham Corporation | OLRCC15 receptor |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
EP0998271B3 (en) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
US6120803A (en) | 1997-08-11 | 2000-09-19 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
AU753205B2 (en) | 1998-05-29 | 2002-10-10 | Catalysts & Chemicals Industries Co., Ltd. | Method of manufacturing photoelectric cell and oxide semiconductor for photoelectric cell |
FR2780405B1 (en) | 1998-06-25 | 2001-12-28 | Centre Nat Rech Scient | NOVEL OLFACTORY RECEPTORS AND USES THEREOF |
TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
GB2354761A (en) | 1999-09-28 | 2001-04-04 | British Sugar Plc | Preparation of benzoyloxy acetic acid derivatives |
US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
EP1125507A1 (en) | 2000-02-15 | 2001-08-22 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Inulin products with improved nutritional properties |
EP1292827A4 (en) | 2000-04-07 | 2006-07-12 | Senomyx Inc | T2r taste receptors and genes encoding same |
TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
AU9619601A (en) | 2000-10-25 | 2002-05-06 | Metcon Medicin Ab | New composition and method for the treatment of dysglucaemia |
US6955887B2 (en) | 2001-03-30 | 2005-10-18 | Senomyx, Inc. | Use of T1R hetero-oligomeric taste receptor to screen for compounds that modulate taste signaling |
US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
JP4744081B2 (en) | 2001-08-31 | 2011-08-10 | ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー | Method for treating disorders using plant extracts |
DE10226203B4 (en) | 2002-06-13 | 2008-04-03 | Südzucker AG Mannheim/Ochsenfurt | Condensed Palatinose, process for its preparation and its use |
EP1572151A1 (en) * | 2002-07-03 | 2005-09-14 | Abbott Laboratories | Liquid dosage forms of proton pump inhibitors |
US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
RU2005141151A (en) | 2003-05-28 | 2006-06-10 | Юнилевер Н.В. (Nl) | FOOD PRODUCTS ENHANCING SATURATION SENSE |
DE602004024982D1 (en) | 2003-05-28 | 2010-02-25 | Unilever Nv | FOOD CONTAINING SATURATION AGENT |
US20050038415A1 (en) | 2003-08-06 | 2005-02-17 | Rohr William L. | Method and apparatus for the treatment of obesity |
US20050244810A1 (en) | 2003-09-29 | 2005-11-03 | Egan Josephine M | Taste signaling in gastrointestinal cells |
WO2005046580A2 (en) | 2003-10-16 | 2005-05-26 | The Regents Of The University Of California | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism |
CN1993113B (en) * | 2004-02-13 | 2010-12-08 | Nod药物公司 | Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof |
US20070032420A1 (en) * | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
EP1888094B1 (en) | 2005-03-31 | 2009-08-12 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
JP2008540437A (en) | 2005-05-03 | 2008-11-20 | ミユーチユアル・フアーマシユーチカルズ・カンパニー・インコーポレーテツド | Controlled release formulation containing quinine |
EP1981595A1 (en) | 2006-01-25 | 2008-10-22 | VIB vzw | Method to control body weight |
US7629134B2 (en) | 2006-07-10 | 2009-12-08 | Duke University | Sour taste receptor compositions and methods |
US20100093861A1 (en) | 2006-09-15 | 2010-04-15 | Stevia Aps | Treatment of insulin resistance or diseases associated with insulin resistance |
US20080107787A1 (en) | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
CN100490789C (en) | 2006-12-22 | 2009-05-27 | 北京亚东生物制药有限公司 | Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof |
US20080274215A1 (en) * | 2007-05-03 | 2008-11-06 | Northern Holdings Inc. | Composition for treatment of cold and flu |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US20080305500A1 (en) | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Novel cell-based assays for identifying enhancers or inhibitors of t1r taste receptors (t1r2/t1r3 sweet) and umami (t1r1/t1r3 umami) taste receptors |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US20080306076A1 (en) | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US20080311192A1 (en) * | 2007-06-12 | 2008-12-18 | Kraft Foods Holdings, Inc. | Enteric-Coated Glucosinolates And Beta-Thioglucosidases |
EP2197433A4 (en) | 2007-08-20 | 2010-09-08 | Sinai School Medicine | Regulating glp-1 and sglt-1 in gastrointestinal cells |
WO2009049105A2 (en) | 2007-10-09 | 2009-04-16 | Gelesis, Inc. | Methods for inducing satiation |
WO2009070311A2 (en) | 2007-11-26 | 2009-06-04 | Teva Pharmaceutical Industries Ltd. | Crystal forms of o-desmethylvenlafaxine fumarate |
WO2010027498A2 (en) | 2008-09-03 | 2010-03-11 | New Science Holdings, Llc | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
KR20110136890A (en) | 2009-04-03 | 2011-12-21 | 디에스엠 아이피 어셋츠 비.브이. | Satiety-inducing composition |
BRPI1013856A2 (en) * | 2009-04-20 | 2016-04-05 | Elcelyx Therapeutics Inc | chemosensitive receptor ligand-based therapies |
DE102009027744A1 (en) | 2009-07-15 | 2011-01-20 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Precursor compounds of sweet receptor antagonists for the prevention or treatment of diseases |
-
2010
- 2010-04-20 US US12/763,926 patent/US9901551B2/en not_active Expired - Fee Related
- 2010-10-19 SG SG10201909796P patent/SG10201909796PA/en unknown
- 2010-10-19 CA CA2800470A patent/CA2800470A1/en not_active Abandoned
- 2010-10-19 JP JP2013506126A patent/JP5907952B2/en active Active
- 2010-10-19 EP EP10850399.6A patent/EP2560660A4/en not_active Withdrawn
- 2010-10-19 WO PCT/US2010/053257 patent/WO2011133180A1/en active Application Filing
- 2010-10-19 KR KR1020127030417A patent/KR101881608B1/en active IP Right Grant
- 2010-10-19 CN CN201610342910.7A patent/CN106039313A/en active Pending
- 2010-10-19 BR BR112012026838A patent/BR112012026838A2/en not_active IP Right Cessation
- 2010-10-19 AR ARP100103817A patent/AR078678A1/en unknown
- 2010-10-19 EA EA201270767A patent/EA201270767A1/en unknown
- 2010-10-19 SG SG10201503098PA patent/SG10201503098PA/en unknown
- 2010-10-19 CN CN201080067558.1A patent/CN102946885B/en not_active Expired - Fee Related
- 2010-10-19 MX MX2012012157A patent/MX2012012157A/en active IP Right Grant
- 2010-10-19 SG SG2012077558A patent/SG184935A1/en unknown
-
2012
- 2012-10-21 IL IL222586A patent/IL222586A0/en unknown
- 2012-11-05 ZA ZA2012/08277A patent/ZA201208277B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2800470A1 (en) | 2011-10-27 |
JP5907952B2 (en) | 2016-04-26 |
CN102946885B (en) | 2016-06-22 |
IL222586A0 (en) | 2012-12-31 |
WO2011133180A1 (en) | 2011-10-27 |
MX2012012157A (en) | 2013-02-26 |
KR20130064743A (en) | 2013-06-18 |
EA201270767A1 (en) | 2013-06-28 |
CN102946885A (en) | 2013-02-27 |
US9901551B2 (en) | 2018-02-27 |
SG10201503098PA (en) | 2015-06-29 |
AR078678A1 (en) | 2011-11-23 |
JP2013525349A (en) | 2013-06-20 |
ZA201208277B (en) | 2014-05-28 |
SG184935A1 (en) | 2012-11-29 |
KR101881608B1 (en) | 2018-07-24 |
US20100267643A1 (en) | 2010-10-21 |
CN106039313A (en) | 2016-10-26 |
BR112012026838A2 (en) | 2016-07-12 |
EP2560660A4 (en) | 2013-11-20 |
EP2560660A1 (en) | 2013-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201909796PA (en) | Chemosensory receptor ligand-based therapies | |
WO2010123930A3 (en) | Chemosensory receptor ligand-based therapies | |
WO2013158928A3 (en) | Chemosensory receptor ligand-based therapies | |
WO2012054526A3 (en) | Chemosensory receptor ligand-based therapies | |
WO2012094636A3 (en) | Chemosensory receptor ligand-based therapies | |
MX2021011939A (en) | Neuroactive compounds and methods of use thereof. | |
GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
MY195289A (en) | Anti IL-36R Antibodies | |
MX2013008702A (en) | Compositions containing glycosylated antibodies and uses thereof. | |
IN2012DN00943A (en) | ||
MX2014003579A (en) | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity. | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
WO2012054527A3 (en) | Chemosensory receptor ligand-based therapies | |
MX2014004074A (en) | Methods of treating liver conditions using notch2 antagonists. | |
MX2012013735A (en) | Neuregulin isoforms, neuregulin polypeptides and uses thereof. | |
PH12015502829A1 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
MX2015017853A (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use. | |
MX2012012094A (en) | Novel synthesis for thiazolidinedione compounds. | |
WO2012054528A3 (en) | Chemosensory receptor ligand-based therapies | |
EA201400623A1 (en) | NEW 2H-INDASOLS AS ANTAGONISTS EP EPCEPTOR | |
MX2014005765A (en) | Tricyclic compounds, compositions comprising them and uses thereof. | |
MY165075A (en) | Pharmaceutical composition comprising fimasartan and hydrochlorothiazide | |
UA108494C2 (en) | Application(rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pirimidine-2-il]amino}phenyl)sulfoximide for treating tumors. | |
WO2012054530A3 (en) | Chemosensory receptor ligand-based therapies |